Urinary Macrophage Migration Inhibitory Factor as a Noninvasive Biomarker in Pediatric Henoch-Schönlein Purpura Nephritis

Purposes The aims of this study were to investigate urinary macrophage migration inhibitory factor (MIF) levels and their clinical significance in Henoch-Schönlein purpura (HSP) children with or without nephritis (N) and to assess the influence of steroid treatment on the urine MIF levels of HSPN patients. Methods Group I comprised 35 children with HSPN who were examined twice (A before treatment and B after steroid treatment). Group II comprised 41 children with HSP. The control group included 32 healthy children. Urinary MIF levels were measured via enzyme linked immunosorbent assay. The levels of serum creatinine, blood urea nitrogen, urinary microalbumin (mAlb), and 24-hour proteinuria were performed to determine their associations with MIF levels. Results Urinary MIF levels were significantly higher in group I compared with group II and the control group (P < 0.01); however, no significant difference was found between group II and the control group (P > 0.05). Upon examination, albeit urinary MIF concentration was significantly lower in group IB compared with group IA (P < 0.05), these concentrations were statistically higher than that of group II (P < 0.05). In addition, in the HSPN patients, the urinary MIF was positively associated with urinary microalbumin and 24-hour proteinuria but no association with serum creatinine and blood urea nitrogen. Conclusions Elevated urinary MIF levels were found to be correlated with proteinuria in pediatric HSPN. An obvious decrease in urinary MIF concentrations among the children with HSPN was associated with steroid treatment. Urinary MIF can be used as a noninvasive biomarker in pediatric HSPN.

[1]  B. Tsao,et al.  Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus , 2017, Lupus.

[2]  L. Leng,et al.  Macrophage migration inhibitory factor drives neutrophil accumulation by facilitating IL‐1β production in a murine model of acute gout , 2016, Journal of leukocyte biology.

[3]  Kyoung-Woon Kim,et al.  Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis , 2016, The Korean journal of internal medicine.

[4]  R. Zwiech Macrophage migration inhibitory factor urinary excretion revisited – MIF a potent predictor of the immunosuppressive treatment outcomes in patients with proliferative primary glomerulonephritis , 2015, BMC Immunology.

[5]  M. Chimenti,et al.  Vasculitides and the Complement System: a Comprehensive Review , 2015, Clinical Reviews in Allergy & Immunology.

[6]  M. Pohl Henoch–Schönlein purpura nephritis , 2015, Pediatric Nephrology.

[7]  R. Coppo,et al.  Henoch–Schönlein purpura nephritis in children , 2014, Nature Reviews Nephrology.

[8]  M. Nowicki,et al.  Polymorphic variants of MIF gene and prognosis in steroid therapy in children with idiopathic nephrotic syndrome. , 2014, Acta biochimica Polonica.

[9]  N. Tomioka,et al.  Macrophage migration inhibitory factor is a possible candidate for the induction of microalbuminuria in diabetic db/db mice. , 2013, Biological & pharmaceutical bulletin.

[10]  Chiou-Feng Lin,et al.  Urinary Macrophage Migration Inhibitory Factor Serves as a Potential Biomarker for Acute Kidney Injury in Patients with Acute Pyelonephritis , 2012, Mediators of inflammation.

[11]  T. Jahnukainen,et al.  Outcome of Henoch–Schönlein purpura 8 years after treatment with a placebo or prednisone at disease onset , 2012, Pediatric Nephrology.

[12]  V. Jeevanandam,et al.  Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. , 2010, American Society of Nephrology. Clinical Journal.

[13]  R. Dodel,et al.  Macrophage Migration Inhibitory Factor in Normal Human Skeletal Muscle and Inflammatory Myopathies , 2010, Journal of neuropathology and experimental neurology.

[14]  A. Bakkaloğlu,et al.  EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria , 2010, Annals of the rheumatic diseases.

[15]  H. Lan Role of Macrophage Migration Inhibition Factor in Kidney Disease , 2008, Nephron Experimental Nephrology.

[16]  M. Hickey,et al.  Targeting leukocytes in immune glomerular diseases. , 2008, Current medicinal chemistry.

[17]  O. Kemmotsu,et al.  Role of macrophage migration inhibitory factor in acute lung injury in mice with acute pancreatitis complicated by endotoxemia. , 2006, American journal of respiratory cell and molecular biology.

[18]  H. Narchi Risk of long term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings: a systematic review , 2005, Archives of Disease in Childhood.

[19]  K. Matsumoto,et al.  Elevated macrophage migration inhibitory factor (MIF) levels in the urine of patients with focal glomerular sclerosis , 2005, Clinical and experimental immunology.

[20]  M. Lam,et al.  Anti-macrophage migration inhibitory factor reduces transforming growth factor-beta 1 expression in experimental IgA nephropathy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  Y. Kawasaki,et al.  Clinical and pathological features of children with Henoch-Schoenlein purpura nephritis: risk factors associated with poor prognosis. , 2003, Clinical nephrology.

[22]  K. Lai,et al.  Polymeric IgA increases the synthesis of macrophage migration inhibitory factor by human mesangial cells in IgA nephropathy. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  R. Atkins,et al.  Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. , 2002, Journal of the American Society of Nephrology : JASN.

[24]  R. Atkins,et al.  The Pathogenic Role of Macrophage Migration Inhibitory Factor in Immunologically Induced Kidney Disease in the Rat , 1997, The Journal of experimental medicine.

[25]  B. Bloom,et al.  Mechanism of a Reaction in Vitro Associated with Delayed-Type Hypersensitivity , 1966, Science.